RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+7.59%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$2.34B
AUM Growth
+$2.34B
(+6.2%)
Cap. Flow
+$80.4M
Cap. Flow
% of AUM
3.44%
Top 10 Holdings %
Top 10 Hldgs %
23.61%
Holding
167
New
20
Increased
59
Reduced
15
Closed
19
Top Buys
| 1 |
AbbVie
ABBV
|
$56.8M |
| 2 |
Bristol-Myers Squibb
BMY
|
$38M |
| 3 |
HCA Healthcare
HCA
|
$36.9M |
| 4 |
Cencora
COR
|
$25.4M |
| 5 |
DaVita
DVA
|
$21.6M |
Top Sells
| 1 |
AAAP
Advanced Accelerator Applications S.A. American Depositary Shares
AAAP
|
$67.4M |
| 2 |
Cigna
CI
|
$65.2M |
| 3 |
Merck
MRK
|
$47.9M |
| 4 |
Johnson & Johnson
JNJ
|
$27.9M |
| 5 |
Willis Towers Watson
WTW
|
$18.5M |
Sector Composition
| 1 | Healthcare | 87.84% |
| 2 | Financials | 1.73% |
| 3 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Align Technology
ALGN
$10.3B
| $16.4M | 0.7% | 65,500 -1,250 | -2% | -$314K |
|
|
XENT
52
DELISTED
Intersect ENT, Inc
XENT
| $16.1M | 0.69% | 410,000 +65,000 | +19% | +$2.55M |
|
53
Zimmer Biomet
ZBH
$21B
| $16.1M | 0.69% | 147,500 +28,500 | +24% | +$3.11M |
|
|
NUVA
54
DELISTED
NuVasive, Inc.
NUVA
| $15.9M | 0.68% | +305,000 | New | +$15.9M |
|
55
Theravance Biopharma
TBPH
$699M
| $15.8M | 0.68% | 652,600 | – | – |
|
56
Incyte
INCY
$16.5B
| $15.2M | 0.65% | 182,500 | – | – |
|
57
Amicus Therapeutics
FOLD
$2.34B
| $15M | 0.64% | 1,000,000 +90,000 | +10% | +$1.35M |
|
58
Hologic
HOLX
$14.9B
| $14.9M | 0.64% | 400,000 +65,000 | +19% | +$2.43M |
|
59
Exact Sciences
EXAS
$8.98B
| $14.9M | 0.64% | 370,500 -64,400 | -15% | -$2.6M |
|
|
ARNA
60
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $14.8M | 0.63% | 375,000 +160,000 | +74% | +$6.32M |
|
61
Biogen
BIIB
$19.4B
| $14.5M | 0.62% | 53,000 | – | – |
|
|
BPMC
62
DELISTED
Blueprint Medicines
BPMC
| $14.5M | 0.62% | 157,753 +11,253 | +8% | +$1.03M |
|
63
FibroGen
FGEN
$47.8M
| $14.3M | 0.61% | 309,500 -15,500 | -5% | -$716K |
|
64
AnaptysBio
ANAB
$569M
| $14.1M | 0.6% | 135,000 -7,400 | -5% | -$770K |
|
65
Inogen
INGN
$216M
| $13.6M | 0.58% | 110,500 +30,500 | +38% | +$3.75M |
|
66
Heron Therapeutics
HRTX
$207M
| $13.1M | 0.56% | 476,000 +226,000 | +90% | +$6.24M |
|
67
VYNE Therapeutics
VYNE
$8.16M
| $12.4M | 0.53% | +330,000 | New | +$12.4M |
|
|
CLVS
68
DELISTED
Clovis Oncology, Inc.
CLVS
| $12.2M | 0.52% | 231,500 | – | – |
|
69
Idexx Laboratories
IDXX
$51.8B
| $12.1M | 0.51% | +63,000 | New | +$12.1M |
|
|
AMRN
70
Amarin Corp
AMRN
$311M
| $12M | 0.51% | 4,000,000 +50,000 | +1% | +$151K |
|
71
Prothena Corp
PRTA
$441M
| $11.7M | 0.5% | 318,500 +8,500 | +3% | +$312K |
|
72
Ardelyx
ARDX
$1.53B
| $11.5M | 0.49% | 2,275,557 | – | – |
|
|
OBSV
73
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $11.3M | 0.48% | 840,000 | – | – |
|
74
Q32 Bio
QTTB
$20.9M
| $10.8M | 0.46% | +575,000 | New | +$10.8M |
|
|
GTHX
75
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $10.6M | 0.45% | 287,000 +72,500 | +34% | +$2.69M |
|